Finance the evidence that can change the decision.
TSCIP can help management define the capital requirement around a bounded evidence milestone and compare structures that preserve strategic optionality.
Capital should buy a decision-relevant milestone.
TSCIP treats financing as an enabling layer around a defined evidence inflection. The core question is not simply how much runway a company can obtain, but what evidence that capital must produce to change a partnering, development or strategic decision.
Capital-to-inflection
Define the evidence milestone first. Then evaluate the amount, timing and form of capital appropriate to reaching it.
Structures may include.
Strategic investment
Capital from a strategic organization where scientific and transaction interests are aligned.
Co-development
Funding tied to a defined development program or evidence package.
Regional licensing
Rights structures that can finance development while preserving selected strategic optionality.
Royalty structures
Royalty monetization or synthetic royalty structures when economics and development stage make them appropriate.
Asset-level financing
Capital ring-fenced around a program or milestone rather than broad corporate runway.
Structured debt
Debt or other structures considered against cash flow, milestone and dilution constraints.
Illustrative market participants.
Pharma venture examples
Pfizer Ventures · Sanofi Ventures · Johnson & Johnson Innovation – JJDC
Royalty / structured-capital examples
Royalty Pharma · HealthCare Royalty (HCRx) · DRI Healthcare
Role boundary.
TSCIP and Nectid provide strategic advisory, diligence and decision-support services. They are not broker-dealers, placement agents, investment banks or securities intermediaries; they do not offer or sell securities, handle investor funds, or receive transaction-based compensation for securities placements. Securities placement should be conducted directly by the company or through an appropriately registered intermediary.